title: Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia.
abstract: Results of the BMF study group trials ALL-REZ 83 and 85 for relapsed acute lymphoblastic leukemia (ALL) are presented. For children with late marrow relapse, remission rates of about 90% were seen in both studies. In children treated for early marrow relapse, the remission rate in study ALL-REZ 85 was superior (86% vs 62%). The probability of event-free survival for all patients and for those with early marrow relapse was also statistically significant (P less than 0.05). Children with T-cell ALL had an extremely unfavourable prognosis in both studies.
authors.affiliation: Kinderklinik, Freie Universität Berlin.
authors.forename: G
authors.initials: G
authors.lastname: Henze
authors.forename: R
authors.initials: R
authors.lastname: Fengler
authors.forename: R
authors.initials: R
authors.lastname: Hartmann
authors.forename: R
authors.initials: R
authors.lastname: Dopfer
authors.forename: U
authors.initials: U
authors.lastname: Göbel
authors.forename: N
authors.initials: N
authors.lastname: Graf
authors.forename: H
authors.initials: H
authors.lastname: Jürgens
authors.forename: D
authors.initials: D
authors.lastname: Niethammer
authors.forename: J
authors.initials: J
authors.lastname: Ritter
authors.forename: G
authors.initials: G
authors.lastname: Schellong
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001855:Bone Marrow Diseases / Q000188:drug therapy* / Q000401:mortality; D016026:Bone Marrow Transplantation; D002648:Child; D003131:Combined Modality Therapy; D006801:Humans; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy* / Q000401:mortality; D011897:Random Allocation; D012008:Recurrence; D012074:Remission Induction; D013997:Time Factors